SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-010438
Filing Date
2023-03-31
Accepted
2023-03-31 17:28:34
Documents
14
Period of Report
2023-03-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 35786
2 ex99-1.htm EX-99.1 88675
3 ex99-1_001.jpg GRAPHIC 3552
  Complete submission text file 0001493152-23-010438.txt   312452

Data Files

Seq Description Document Type Size
4 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ocx-20230331.xsd EX-101.SCH 3224
5 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ocx-20230331_lab.xml EX-101.LAB 34240
6 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ocx-20230331_pre.xml EX-101.PRE 22358
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3457
Mailing Address 15 CUSHING IRVINE CA 92618
Business Address 15 CUSHING IRVINE CA 92618 949-409-7600
Oncocyte Corp (Filer) CIK: 0001642380 (see all company filings)

IRS No.: 271041563 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37648 | Film No.: 23789362
SIC: 2835 In Vitro & In Vivo Diagnostic Substances